 I want to propose this phase 3 trial in renal cell carcinoma that just opened. This is Meteor, phase 3 randomized study of Cabuzentinib, a dual VEGF met inhibitor versus Iverolimus and subject with metastatic clear cell renal cell carcinoma. As an introduction, this audience know well the role of VEGF and met in RCC. In fact, VHL gene dysfunction predominant in clear cell RCC leads to impaired hip degradation which transcriptionally activates not only the VEGF pathway but also the met pathway. We know well that activated met result in invasive RCC phenotype and we learn from Dr. Gibney and colleagues that higher met expression in clear cell RCC correlate with worse disease specific survival and is completely an independent predictor of survival. We also know from a very important work for Senino et al. that resistance to VEGF pathway target agent can be overcome by inhibition of met. Cabuzentinib is a dual VEGF met tyrosine kinase inhibitor that showed preliminary activity as an investigational agent in multiple solid tumor including renal cell carcinoma in a work that we presented at the 2012 ASCO meeting. This is the design of the phase three metayore study. This will be an open label randomized phase three study of 200 sites primarily in North America and Europe. Patient with metastatic renal cell carcinoma 650 with clear cell histology measurable disease and who progressed on prior VEGF tyrosine kinase inhibitor will be randomized one to one to Cabuzentinib at 60 milligram once a day versus Iverolimus at 10 milligram once a day. It will be again a one to one randomization without crossover. The primary endpoint is progression free survival for independent radiology review and the secondary endpoint are overall survival and objective response rate. These are the statistics. The primary endpoint is PFS analysis for independent radiology committee. We assume five months PFS 4.9 in fact on the Iverolimus trial the record one 259 events are required among the first 375 randomized patient. This is designed to have a 90% power to detect a 50% meaningful improvement in medium PFS from five to 7.5 months which correspond to a hazard ratio of 0.66. We will have power for a secondary endpoint of OS assuming 15 months OS on record one trial with 408 event are required to provide 80% power for a 33% improvement in median OS from 15 to 20 months. There will be a single interim analysis of OS at the time of the primary PFS analysis. In term of additional end point on the study the duration of response the safety and tolerability, pharmacokinetics and to health related quality of life with the help of Dr. Sella, the NCCN functional assessment of cancer therapy, the fact kidney symptom index questionnaire as well as the European health questionnaire will look also a skeletal related event especially with the data with Cabos Antenim in prostate cancer as well as an array of biomarker. In term of key eligibility criteria RCC with clear cell component and measurable disease prior treatment was at least one VEGF targeting TKI no prior treatment was an mTOR inhibitor and for the most recently received VEGF TKI patient need to have progressed during the treatment or treated for at least four weeks and progressed within six months after the last dose. The last dose must have been within six months before randomization and this trial has no limit on the number of additional anti-cancer therapies and in fact it allows patient with brain metastasis and if my voice bored you you only need to go to the Meteor clinical trial dot com and everything will be there. Thank you very much.